Drug intelligence / Profile preview

Aspergillus oryzae + Pancreatin

Development stage: Phase 4
Lead developer: Edward Keller
Modality: Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Oral

Overview

This drug is a combination of Aspergillus oryzae extract and pancreatin, used to supplement digestive enzymes and improve digestion in cases of enzyme deficiency. It contains enzymes such as amylase, lipase, and protease from pancreatin, and cellulase from Aspergillus oryzae, which helps break down plant cell walls and carbohydrates.

Brand names: Combizym慷彼申
Other names: 米曲菌胰酶

Targets

LCT (Lactase-phlorizin hydrolase)

Beyond the preview

Go deeper on Aspergillus oryzae + Pancreatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aspergillus oryzae + Pancreatin.

Explore the full profile